Alector, Genentech Ink Deal for Parkinson Therapy AL050

Alector has entered a global license agreement with Genentech, a member of the Roche Group, granting Genentech exclusive worldwide rights to develop and commercialize AL050, Alector's investigational, brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy for Parkinson disease and other neurodegenerative diseases, Alector announced October 5, 2026.¹ Under the agreement, Alector will receive a $100 million upfront payment, with the potential for up to $1.17 billion in additional milestone payments, plus tiered royalties on net sales.¹

Why did Alector seek this partnership?

"Deficient GCase activity is increasingly recognized as a contributor to Parkinson's Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency," said Arnon Rosenthal, PhD, CEO of Alector, in a company press release.¹ "The challenge in treating GCase deficiency is twofold: engineering an enzyme with optimal activity and durability and successfully delivering it to the brain. AL050 addresses this by pairing an engineered GCase enzyme with our proprietary Alector Brain Carrier technology designed to cross the blood-brain barrier. Genentech's long-standing commitment to Parkinson's Disease makes them an ideal partner as this program moves toward the clinic."

What problem is AL050 designed to address?

GCase deficiency is increasingly recognized as a driver of neurodegeneration in Parkinson disease, most pronounced in, but not limited to, carriers of GBA1 mutations, which occur in 8-12% of sporadic Parkinson disease cases.² AL050 pairs an Alector-engineered GCase enzyme, optimized for greater enzymatic activity and a longer half-life, with Alector Brain Carrier (ABC), the company's proprietary platform designed to transport therapeutics across the blood-brain barrier.¹ Delivered into the brain, the enzyme is intended to break down glucosylsphingosine and glucosylceramide, lipids that accumulate in neurons and other brain cells when GCase is deficient and that drive lysosomal dysfunction and alpha-synuclein aggregation, with the aim of reducing cellular dysfunction and slowing disease progression.¹^,²

A similar brain-shuttle construct pairing GCase with a transferrin receptor-binding module previously achieved 8- to 10-fold greater substrate reduction in mouse brain tissue than the enzyme alone.³ Alector designed ABC to achieve deeper brain penetration at lower doses, with the goal of improving patient outcomes while reducing costs, and is applying the platform across its broader pipeline beyond AL050.¹

What are the terms of the agreement?

Under the agreement, Genentech will be responsible for development, regulatory, manufacturing, and commercialization of AL050 across all indications, while Alector retains ownership of ABC and full rights to apply the platform across its wholly owned pipeline.¹

"Parkinson's Disease is one of the fastest-growing neurological conditions worldwide,” Boris L. Zaïtra, head of Roche Corporate Business Development, said in the release.¹ “By partnering with companies such as Alector we aim to delay or halt the progression of Parkinson's so patients maintain and prolong their independence."

What does the deal mean for Alector's own pipeline?

Dr Rosenthal said the partnership extends Alector's cash runway into 2029, funding continued development of its subcutaneously delivered, brain-enabled anti-amyloid-beta antibody toward multi-cohort clinical data in Alzheimer disease patients, along with its brain-enabled tau short interfereing RNA (siRNA) and alpha-synuclein siRNA programs through investigational new drug (IND)-enabling studies and IND filings.¹ Alector plans to host a scientific webinar on October 13, 2026, on its wholly owned pipeline, covering AL137, its anti-amyloid-beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program.¹

What are the limitations?

AL050 remains in preclinical development, so no clinical safety or efficacy data in patients exist yet, and Genentech's development and regulatory timeline for the program was not disclosed. The milestone payments are contingent on development, regulatory, and commercial targets that may not be achieved, and the $1.17 billion figure represents a maximum potential total rather than a guaranteed sum.

References

1. Alector. Alector enters global license agreement with Genentech for brain penetrant GCase enzyme replacement therapy for Parkinson's Disease and other neurodegenerative diseases. Press release. Published October 5, 2026. Accessed October 6, 2026. https://investors.alector.com/news-releases/news-release-details/alector-enters-global-license-agreement-genentech-brain
2. Avenali M, Blandini F, Cerri S. Glucocerebrosidase defects as a major risk factor for Parkinson's disease. Front Aging Neurosci. 2020;12:97. doi:10.3389/fnagi.2020.00097
3. Gehrlein A, Udayar V, Anastasi N, et al. Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14(1):2057. doi:10.1038/s41467-023-37632-4